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Abstract: The purpose of this study was to evaluate the effect of three-weeks ochratoxin A
(OTA) exposure on some lipid peroxidation parameters, reduced glutathione concentration and
glutathione-peroxidase activity, as well as expression of oxidative stress response-related (KEAP1,
NRF2) and glutathione system (GPX3, GPX4, GSS, GSR) genes in chickens. Three levels of exposure
(106, 654 and 1126 µg/kg feed) were applied. The results showed that OTA initiated free radical
formation, which was suggested by the increase in the malondialdehyde content in the liver and
kidney, which was more marked in the liver, depending on the length of exposure and dose.
Reduced glutathione concentration increased as an effect of the highest OTA dose in blood plasma
and in liver, but not in red blood cell hemolysates and the kidney. Glutathione peroxidase activity
did not change in the blood and showed increasing tendency in the liver, and significant increase
in the kidney. Expression of KEAP1 gene showed up-regulation in the liver, and down-regulation
in the kidney, but overexpression of NRF2 gene was found in the liver and kidney at the highest
dose. However, down-regulation of Nrf2 dependent genes, GPX3, GPX4, GSS and GSR, suggested an
improper antioxidant response at the protein level, thus oxidative stress occurred, even at the dose of
the EU regulatory limit for poultry diets.
Keywords: Ochratoxin A; glutathione; glutathione-peroxidase; oxidative stress; gene expression
1. Introduction
Ochratoxin A (OTA) is a secondary metabolite of certain species of the Aspergillus and Penicillium
genus [1]. The chemical structure of OTA consists of weak organic acids with a dihydroisocumarin
moiety joined by a peptide bond to 1-phenylalanine [2]. There are three ochratoxin forms, designated as
A, B and C, which have slight structural differences; however, ochratoxin A (OTA) is chlorinated and is
the most toxic one [3]. OTA contamination in Europe in the year 2018, according to the recent Biomin
World Mycotoxin Survey Report [4] was 40% in the finished (complete) feeds and 12% in cereals,
with the average of positive samples containing 4 µg/kg in finished feeds and 19 µg/kg in cereals,
respectively. OTA has a similar structure to the amino acid phenylalanine, therefore it can impair
protein synthesis [5]. OTA is very stable during feed-processing, hence it cannot be eliminated from
the feed industry, and remains intact and biologically active in the finished feed. Chicken is sensitive
to OTA, LD50 value at 21 days of age is 3.6 ± 0.6 mg/kg b.w. [6].
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OTA has nephrotoxic [7,8], mutagenic [9], carcinogenic [9], teratogenic [10] and
immunosuppressive [11,12] effects in animals and humans. However, not all of the aforementioned
toxic effects have been proven in poultry species. An immune suppressive effect was found even at the
European Union maximum proposed level (0.1 mg/kg feed) in broiler chicken [13]. After absorption,
OTA was present at the highest amount in the blood, followed by—in a decreasing order—the
kidneys, liver, muscle and adipose tissue [14]. Feeding OTA-contaminated feed to broiler chicken
(2.5 mg OTA/kg) caused a significant reduction in body-weight gain, and the relative kidney weight
increased [15].
OTA affects the expression of several genes related to cell damage, apoptosis, cellular stress and
antioxidant defence systems [16]. The mechanism of OTA toxicity includes the formation of oxygen
free radicals and consequently peroxidation of polyunsaturated fatty acids [17]. This is supported
by those results which are proving that low molecular weight antioxidants, such as tocopherol
or ascorbic acid, decrease the formation of lipid peroxides and the corresponding toxic effects of
ochratoxin A [18]. Molecular mechanisms responding to oxidative stress are conserved in vertebrates,
including poultry. The master regulator of the oxidative stress response is the transcription factor
nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) [19] in connection with Kelch-like ECH-associated
protein 1 (Keap1) [20]. OTA-induced oxidative stress has an effect on both enzymatic and non-enzymatic
antioxidant defences [21], and also modulates Nrf2 gene and protein expression, which regulates
the expression of the Antioxidant Response Element gene cluster [22]. In response to an elevated
ROS level, Nrf2 induces the expression of antioxidant enzymes, which are the key component of the
glutathione (GSH) biosynthesis pathway [23]. Changes in the redox balance of the cells regulate the
protein expression of Nrf2 and its activity. Under unstressed conditions, Nrf2 is bounded to Keap1 to
promote Nrf2 ubiquitination and further enzymatic degradation in proteasomes [24], resulting in low
basal Nrf2 activity. However, in an oxidative stress situation the activity increases, due to the oxidation
of Keap1 cysteine side chains, as an oxidative stress sensor. Consequently, the interaction between
Nrf2 and Keap1 destabilizes and allows nuclear translocation of Nrf2 to transcribe its specific target
genes [25]. Many Nrf2-regulated enzymes are involved in the antioxidant defence [26] and expression
of most of them is inhibited by OTA treatment in the kidney of chicken [27]. However, there is no data
available about the effect of OTA on glutathione redox system.
The purpose of the present study was to evaluate the toxic effect of OTA related to peroxidation of
unsaturated fatty acids and on the other side, the oxidative stress response in the liver and kidney
of chickens. For this purpose, a sub-chronic in vivo toxicological experiment was applied, in which
markers of peroxidation of lipids, amount and activity of the glutathione redox system and expression
of several genes regulating their biosynthesis or repair were analysed.
2. Materials and Methods
2.1. Production and Determination of Ochratoxin A
Ochratoxin A was produced by artificial infection of sterile ground corn substrate with an
Aspegillus albertensis strain (SZMC 22107) deposited in the Microbiological Collection of the University
of Szeged. Ochratoxin A was determined by the high performance liquid chromatography (HPLC)
method with fluorescence detection according to [28] after immune-affinity clean-up with OchraStar R
IAC column (RomerLabs, Tulln) in triplicates. Predicted and measured OTA content of the complete
feed is shown in Table 1.
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Table 1. Predicted and measured ochratoxin A concentration in the complete feed.
Group Predicted OTA (µg/kg) Measured OTA (µg/kg)
Control 0 <57
O1 100 106 ± 10.5
O2 500 654 ± 65.2
O3 1000 1126 ± 93.7
2.2. Animals, Treatments and Sample Preparations
A total of 78 broiler chickens (21 days of age) were used for the experiment. Animals had free
access to feed and water. Effect of OTA toxicity was investigated in three different dosage groups:
Control; low (O1: 106 µg/kg feed), medium (O2: 654 µg/kg feed) and high (O3: 1126 µg/kg feed).
The doses were calculated based on the European Commission recommendation (2006/576/EC) for
OTA in chicken complete feed (100 µg/kg), namely 1×, 5× and 10× of the recommendation levels were
used as predicted doses, which were validated by analysis (Table 1). An OTA-contaminated diet was
fed for 21 days. At each sampling, on 28, 35 and 42 days of age, six animals from each experimental
group were investigated. Birds were euthanized by cervical dislocation, blood was collected on ice,
the liver and kidney were removed, collected on ice, and all samples stored at −70 ◦C until analysis.
For gene expression studies, portions of liver and kidney were frozen in liquid nitrogen immediately
after sampling, and stored at −70 ◦C until the analysis to prevent RNA degradation.
All procedures were conducted in accordance with the guidelines set by the European
Communities Council Directive (86/609 EEC) and the protocol was approved by the Food Chain Safety,
Land use, Plant and Soil Protection and Forestry Directorate of the Pest County Governmental Office
(PE/EA/1964-7/2017) with the limitation to use as low a number of animals as possible for an accurate
statistical analysis.
2.3. Determination of Lipid Peroxidation and Antioxidant Parameters
Markers of the initial phase of lipid peroxidation in the liver, the amount of conjugated dienes
(CD) and conjugated trienes (CT), was measured by the absorbance of samples at 232 nm and
268 nm after extraction in 2,2,4-trimethylpentane (Reanal, Budapest) [29]. The other analyses were
made from blood plasma, red blood cell hemolysate (1:9 v/v) in redistilled water, and in tissue
homogenates which was prepared with 9-fold volume of cold (4 ◦C) physiological saline (0.65% w/v
NaCl). Thiobarbituric reactive substances content, was used as the marker of terminal phase of lipid
peroxidation and was measured in the native homogenate of liver and kidney according to the method
of [30], and expressed as malondialdehyde, which served as the standard (1,1,3,3 tetraethoxypropane,
Fluka, Buchs). Reduced glutathione (GSH) concentration and glutathione-peroxidase (GPx) activity was
measured in the 10,000 g supernatant fraction of liver and kidney homogenates by Ellmann’s reagent
(5,5’-dithiobis-(2-nitrobenzoic) acid, Sigma, St. Louis) according to the method of [31], and according
to [32] using cumene-hydroperoxide (Sigma, St. Louis) and reduced glutathione (Reanal, Budapest) as
co-substrates, respectively. GSH content and GPx activity were calculated to protein content, which was
determined by the biuret method in blood plasma and red blood cell hemolysate [33], and using
Folin-phenol reagent (Merck, Darmstadt) according to the method of [34] in the 10,000 g supernatant
fraction of liver and kidney homogenates.
2.4. Quantitative Real-Time PCR
The purification of total RNA was carried out by NucleoZOL reagent (Macherey-Nagel, Düren)
from 6–10 mg liver homogenates, according to the manufacturer’s instructions. DNase I treatment
was performed after RNA extraction according to the protocol of the supplier (Thermo Fisher
Scientific, San Jose) to remove any genomic DNA contamination. Agarose gel electrophoresis and
NanoPhotometer (Implen, Munich) measurement was carried out to verify the quantity and integrity of
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total RNA samples. Furthermore, only those samples were accepted, which had the ratios of absorption
260:280 nm at >2.0. The cDNA production was implemented by RevertAID reverse transcriptase
(Thermo Fisher Scientific, San Jose) and random nanomer primer from 1 µg of total RNA as described by
the standard protocol. The primers used for the quantification of the mRNA transcriptional levels of the
target (KEAP1; NRF2; GPX3: Extracellular glutathione peroxidase; GPX4: Phospholipid hydroperoxide
glutathione peroxidase, GSS: Glutathione synthetase and GSR: Glutathione reductase) and endogenous
control genes (GAPDH) are shown in Table 2 and were designed by Primer Express 3.0.1 (Thermo Fisher
Scientific, San Jose). GAPDH, as an endogenous control gene, was chosen according to literature as it
had no known interaction with oxidative stress and mycotoxin exposure in broiler chickens as it was
applied as a housekeeping control gene in several other studies [35–37].
Table 2. Primers of target (GPX4, GPX3, GSS, GSR, NRF2, KEAP1) and endogenous control
(GAPDH) genes.
Gene Forward (5’-3’) Reverse (5’-3’) GenBank Accession Nr.
GAPDH TGACCTGCCGTCTGGAGAAA TGTGTATCCTAGGATGCCCTTCAG NM_204305.1
KEAP1 CATCGGCATCGCCAACTT TGAAGAACTCCTCCTGCTTGGA XM_025145847.1
NRF2 TTTTCGCAGAGCACAGATAC GGAGAAGCCTCATTGTCATC NM_205117.1
GPX3 ATCCCCTTCCGAAAGTACGC GACGACAAGTCCATAGGGCC NM_001163232.2
GPX4 AGTGCCATCAAGTGGAACTTCAC TTCAAGGCAGGCCGTCAT NM_001346448.1
GSS GTACTCACTGGATGTGGGTGAAGA CGGCTCGATCTTGTCCATCAG XM_425692.6
GSR CCACCAGAAAGGGGATCTACG ACAGAGATGGCTTCATCTTCAGTG XM_015276627.2
Quantitative real-time PCR measurements, in the case of GPX4, GSS and GSR genes, were
performed in duplexes (GAPDH and one target gene), using MGB TaqMan probes shown in Table 3
(Thermo Fisher Scientific, San Jose) as described previously [38].
Table 3. Dual labelled probes for target and endogenous control genes. MGB-NFQ quencher was used
in all probes.
Gene MGM-NFQ Dual Labelled Probe 5’-3’ Fluorescent Dye
GAPDH CCAGCCAAGTATGATGAT VIC
GPX4 CAGCCCAATGGAG FAM
GSS AGGAGGGAACAACCTG FAM
GSR CTGGACTTCGGCTC FAM
The measurements were carried out with pooled cDNA templates in both cases. The pools were
formed from equal (100 ng) amounts of cDNA per 6 chicken livers of each sampled group at each
sampling point of treatment in five technical replicates. Based on the results of previous experiments,
no measurable differences were found if the determination was made from pooled and not individual
samples. Moreover, no template controls (NTC) were applied for each of the PCR measurements.
The PCR profile for the GPX4, GSS, GSR, GPX3 and KEAP1 target genes consisted of 95 ◦C for
10 min for pre-amplification denaturation (PAD), and 95 ◦C for 15 s, 58 ◦C for 30 s and 72 ◦C for 30 s
for 45 cycles. The PCR profile for the NRF2 target gene was 95 ◦C for 10 min for pre-amplification
denaturation (PAD), and 95 ◦C for 15 s, 60 ◦C for 30 s and 72 ◦C for 30 s for 45 cycles. In case of
the duplexes (GPX4, GSS and GSR) both VIC and FAM signals, while in the case of singleplexes
(GPX3, KEAP1 and NRF2) SYBR Green signals were detected at the end of the extension period.
Amplified products were verified by gel electrophoresis, while in the case of singleplexes, melting curve
analysis was also performed. The threshold cycle (Ct) of the target genes (GPX4, GPX3, NRF2, KEAP1,
GSS andGSR) and the endogenous control gene (GAPDH) was determined by StepOne™/StepOnePlus™
Software v2.2 (Thermo Fisher Scientific, San Jose) applying the comparative Ct method. The delta Ct
(∆Ct), delta-delta Ct (∆∆Ct) and relative quantification (RQ = 2−∆∆Ct) values were calculated by the
formula described in [39].
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2.5. Statistical Analysis
Data were expressed as means ± SD. The data were first subjected to a Kolmogorov–Smirnov
normality test, and homogeneity of variance was confirmed by the Barlett test. Data passing both
tests were analysed by one-way ANOVA followed by Tukey’s post hoc test. Statistical analysis was
performed using GraphPad PRISM version 7 software (GraphPad, San Diego), and p ≤ 0.05 was
considered significant.
3. Results
3.1. Clinical Findings
Clinical signs of toxicity and mortality were not observed during the trial in the
experimental groups.
3.2. Effect of Long-Term Ochratoxin A Exposure on Lipid Peroxidation and Glutathione Redox System in
Chicken Liver
Markers of the initial phase of lipid peroxidation, conjugated dienes and trienes, did not change
significantly in the liver as an effect of different OTA doses (data not shown). The termination phase
marker, a meta-stable end product (malondialdehyde), also did not change in blood plasma and red
blood cell hemolysates (data not shown), but increased in the liver at all samplings, and at day 7 in the
kidney of the highest (O3) dose group as compared to the control (Table 4).
Table 4. Effect of Ochratoxin A on malondialdehyde content in liver and kidney homogenates
(mean ± SD; n = 6).
Malondialdehyde in Liver Homogenate (µmol/g Wet Weight Tissue)
Day 0 Day 7 Day 14 Day 21
Control 64.46 ± 11.23 49.89 ± 6.49 a 43.71 ± 14.24 a 58.21 ± 5.89 a
O1 57.21 ± 11.54 ab 59.83 ± 7.31 ab 61.54 ± 14.95 ab
O2 56.79 ± 13.57 ab 62.34 ± 15.11 ab 56.53 ± 9.91 a
O3 77.59 ± 28.07 b 74.28 ± 18.64 b 77.41 ± 8.39 b
Malondialdehyde in Kidney Homogenate (µmol/g Wet Weight Tissue)
Day 0 Day 7 Day 14 Day 21
Control 36.32 ± 10.10 41.11 ± 7.98 a 41.03 ± 12.27 46.19 ± 5.37
O1 42.38 ± 9.19 ab 42.55 ± 12.39 44.14 ± 2.67
O2 46.25 ± 11.94 ab 43.65 ± 9.19 41.32 ± 9.68
O3 57.93 ± 7.44 b 50.75 ± 8.14 45.23 ± 3.08
a,b Different superscripts in the same column mean significant difference at p < 0.05 level. O1: 106 µg OTA/kg feed,
O2: 654 µg OTA/kg feed, O3: 1126 µg OTA/kg feed.
The non-enzymatic part of the glutathione redox system, GSH concentration, increased significantly
as an effect of the highest dose of OTA exposure (O3) in blood plasma on day 7, and also in the
10,000 g supernatant fraction of liver homogenate on days 14 and 21 as compared to the control
(Table 5). There were no significant alterations in GSH content of red blood cell hemolysates and
kidney homogenates (data not shown).
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Table 5. Effect of Ochratoxin A treatment on reduced glutathione concentration in blood plasma and
liver homogenates (mean ± SD; n = 6).
Blood Plasma (µmol/g Protein)
Day 0 Day 7 Day 14 Day 21
Control 11.47 ± 1.91 11.70 ± 1.65 a 11.91 ± 2.67 11.68 ± 1.00
O1 12.15 ± 2.42 a 12.10 ± 1.74 12.42 ± 2.16
O2 14.51 ± 1.89 a 13.28 ± 1.58 11.80 ± 1.50
O3 17.78 ± 1.29 b 12.75 ± 2.00 13.26 ± 1.60
Liver (µmol/g 10,000 g Supernatant Protein)
Day 0 Day 7 Day 14 Day 21
Control 3.25 ± 0.37 5.22 ± 1.30 5.24 ± 0.53 a 4.08 ± 0.53 ab
O1 5.69 ± 0.78 5.21 ± 0.62 a 3.44 ± 0.32 a
O2 6.58 ± 1.04 6.04 ± 1.33 ab 4.39 ± 1.27 ab
O3 6.73 ± 1.77 7.73 ± 1.85 b 5.42 ± 0.93 b
a,b Different superscripts in the same column mean significant difference at p < 0.05 level. O1: 106 µg OTA/kg feed,
O2: 654 µg OTA/kg feed, O3: 1126 µg OTA/kg feed.
There were no differences in the GPx activity in blood plasma and red blood cell hemolysates
(data not shown), while increasing tendency was found in liver homogenates at days 7 and 14 in the
moderate and highest dose groups (O2 and O3), and a significant increase in kidney homogenates at
day 7 in the highest (O3) dose group as compared to the control (Table 6).
Table 6. Effect of Ochratoxin A treatment on glutathione peroxidase activity in liver and kidney
homogenates (mean ± SD; n = 6).
Liver (U/g 10,000 g Supernatant Protein)
Day 0 Day 7 Day 14 Day 21
Control 1.76 ± 0.63 3.13 ± 1.17 3.15 ± 1.40 2.70 ± 0.99
O1 3.01 ± 0.96 3.05 ± 0.71 2.01 ± 0.71
O2 4.21 ± 1.59 3.91 ± 1.55 2.35 ± 1.27
O3 4.13 ± 1.45 4.76 ± 2.23 3.40 ± 1.04
Kidney (U/g 10,000 g Supernatant Protein)
Day 0 Day 7 Day 14 Day 21
Control 2.26 ± 0.43 2.24 ± 0.27 a 2.79 ± 0.22 2.27 ± 0.71
O1 2.60 ± 0.26 ab 2.69 ± 0.47 2.39 ± 0.11
O2 2.63 ± 0.28 ab 2.59 ± 0.66 2.72 ± 0.28
O3 2.94 ± 0.26 b 2.75 ± 0.48 2.62 ± 0.31
a,b Different superscripts in the same column mean significant difference at p < 0.05 level. O1: 106 µg OTA/kg feed,
O2: 654 µg OTA/kg feed, O3: 1126 µg OTA/kg feed.
3.3. Effect of Long-Term Ochratoxin A Exposure on Expression of Genes Encoding Components of Glutathione
System and Required for Their Synthesis or Repair in Liver and Kidney
The relative expression of the KEAP1 gene was significantly higher in the liver on day 14 in the
moderate and high dose groups (O2 and O3), but lower in kidney on days 7 and 14 in the O2 group,
and on day 21 in the O1 and O2 groups than the control (Table 7). Overexpression of the NRF2 gene was
found in liver and kidney at all sampling times in the O3 group as compared to the control (Table 7).
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Table 7. Effect of Ochratoxin A treatment on the relative expression of KEAP1, NRF2 genes in the liver
and kidney of broiler chickens (mean ± SD; n = 6 in a pool, equal amounts of cDNA per individual).
Kelch-Like ECH-Associated Protein 1 (KEAP1)
Day 0 Day 7 Day 14 Day 21
Liver
Control 1.00 ± 0.05 0.71 ± 0.08 0.90 ± 0.08 a 1.00 ± 0.16
O1 0.71 ± 0.10 0.93 ± 0.13 a 0.91 ± 0.18
O2 0.69 ± 0.06 1.19 ± 0.15 b 1.01 ± 0.14
O3 0.76 ± 0.14 1.27 ± 0.08 b 1.09 ± 0.24
Kidney
Control 1.00 ± 0.06 1.00 ± 0.14 b 1.15 ± 0.09 b 1.39 ± 0.22 b
O1 0.97 ± 0.11 b 0.95 ± 0.10 ab 1.11 ± 0.20 a
O2 0.73 ± 0.07 a 0.92 ± 0.21 a 0.94 ± 0.08 a
O3 0.85 ± 0.05 ab 0.96 ± 0.06 ab 1.17 ± 0.13 ab
Nuclear Factor-Erythroid 2 p45-Related Factor 2 (NRF2)
Day 0 Day 7 Day 14 Day 21
Liver
Control 1.00 ± 0.06 1.19 ± 0.24 a 1.52 ± 0.27 ab 1.20 ± 0.20 a
O1 1.07 ± 0.23 a 1.21 ± 0.23 a 1.21 ± 0.22 a
O2 1.36 ± 0.28 ab 1.23 ± 0.24 a 1.46 ± 0.30 a
O3 1.68 ± 0.25 b 1.87 ± 0.22 b 1.85 ± 0.31 b
Kidney
Control 1.01 ± 0.12 0.89 ± 0.07 a 0.95 ± 0.19 a 1.04 ± 0.12 a
O1 0.79 ± 0.14 a 0.92 ± 0.15 a 0.95 ± 0.16 a
O2 0.80 ± 0.13 a 0.98 ± 0.15 a 0.96 ± 0.09 a
O3 1.22 ± 0.14 b 1.39 ± 0.25 b 1.29 ± 0.23 b
a,b Different superscripts in the same column mean significant difference at p < 0.05 level. O1: 106 µg OTA/kg feed,
O2: 654 µg OTA/kg feed, O3: 1126 µg OTA/kg feed.
In the case of GPX3 expression, opposite tendencies were found at day 7 between the liver and
kidney. It was downregulated in the liver but upregulated in the kidney in the O1 group (Table 8).
At day 14, similar changes were found in the liver and kidney, overexpression of GPX3 was found in
the O3 group. One week later, at day 21, GPX3 expression was downregulated in all treatment groups
in the liver, and upregulated in the kidney in the O3 group (Table 8). GPX4 expression did not change
markedly in the liver, but it was significantly downregulated at day 7 in O2 and O3 groups, and in all
OTA treated groups at day 14 and 21 in the kidney. GSS gene expression was lower as an effect of
the lowest (O1) dose in the liver at day 14. In the kidney, downregulation of the GSS gene was found
on day 7 in the two higher dose groups (O2 and O3), and on day 14 in the lowest dose group (O1) as
compared to the control (Table 8).
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Table 8. Effect of Ochratoxin A treatment on the relative expression of GPX3, GPX4 genes in liver and
kidney of broiler chickens (mean ± SD; n = 6 in a pool, equal amounts of cDNA per individual).
Glutathione Peroxidase 3 (GPX3)
Day 0 Day 7 Day 14 Day 21
Liver
Control 1.00 ± 0.03 0.84 ± 0.10 b 0.99 ± 0.16 a 1.49 ± 0.14 c
O1 0.59 ± 0.15 a 0.95 ± 0.18 a 0.86 ± 0.10 a
O2 0.73 ± 0.11 ab 1.05 ± 0.11 ab 0.89 ± 0.12 a
O3 0.84 ± 0.19 b 1.24 ± 0.09 a 1.24 ± 0.13 b
Kidney
Control 1.00 ± 0.03 0.83 ± 0.06 a 0.94 ± 0.08 a 1.05 ± 0.06 a
O1 0.90 ± 0.08 a 0.99 ± 0.01 ab 1.10 ± 0.11 a
O2 0.96 ± 0.11 a 0.99 ± 0.09 ab 1.00 ± 0.08 a
O3 1.60 ± 0.10 b 1.56 ± 0.14 b 1.47 ± 0.15 b
Glutathione Peroxidase 4 (GPX4)
Day 0 Day 7 Day 14 Day 21
Liver
Control 1.00 ± 0.05 0.51 ± 0.02 0.40 ± 0.03 ab 0.53 ± 0.03
O1 0.49 ± 0.02 0.32 ± 0.01 a 0.51 ± 0.03
O2 0.50 ± 0.05 0.42 ± 0.03 b 0.54 ± 0.04
O3 0.51 ± 0.06 0.42 ± 0.10 ab 0.49 ± 0.01
Kidney
Control 1.00 ± 0.05 0.48 ± 0.03 b 0.52 ± 0.03 c 1.25 ± 0.04 c
O1 0.49 ± 0.02 b 0.32 ± 0.01 a 0.90 ± 0.03 b
O2 0.40 ± 0.02 a 0.35 ± 0.02 ab 0.72 ± 0.04 a
O3 0.37 ± 0.03 a 0.36 ± 0.03 b 0.75 ± 0.04 a
a,b Different superscripts in the same column mean significant difference at p < 0.05 level. O1: 106 µg OTA/kg feed,
O2: 654 µg OTA/kg feed, O3: 1126 µg OTA/kg feed.
Expression of GSS and GSR genes were downregulated in the lowest dose group (O1) on day 14
in both the liver and kidney (Table 9).
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Table 9. Effect of Ochratoxin A treatment on the relative expression of GSS and GSR genes in the liver
and kidney of broiler chickens (mean ± SD; n = 6 in a pool, equal amounts of cDNA per individual).
Glutathione Synthetase (GSS)
Day 0 Day 7 Day 14 Day 21
Liver
Control 1.00 ± 0.03 0.73 ± 0.09 1.25 ± 0.17 b 0.93 ± 0.13
O1 0.71 ± 0.09 0.83 ± 0.09 a 0.76 ± 0.31
O2 0.74 ± 0.10 1.06 ± 0.19 ab 0.78 ± 0.20
O3 0.70 ± 0.12 1.19 ± 0.25 b 0.57 ± 0.10
Kidney
Control 1.00 ± 0.08 0.96 ± 0.14 ab 1.11 ± 0.07 b 0.84 ± 0.17
O1 1.08 ± 0.17 b 0.83 ± 0.09 a 0.79 ± 0.14
O2 0.81 ± 0.15 a 1.01 ± 0.10 b 0.82 ± 0.08
O3 0.82 ± 0.16 a 0.98 ± 0.13 ab 0.80 ± 0.07
Glutathione Reductase (GSR)
Day 0 Day 7 Day 14 Day 21
Liver
Control 1.00 ± 0.10 0.48 ± 0.04 0.60 ± 0.06 b 0.47 ± 0.05
O1 0.51 ± 0.09 0.34 ± 0.06 a 0.52 ± 0.06
O2 0.54 ± 0.04 0.60 ± 0.09 b 0.48 ± 0.03
O3 0.50 ± 0.08 0.54 ± 0.05 b 0.47 ± 0.08
Kidney
Control 1.00 ± 0.04 0.99 ± 0.10 0.95 ± 0.13 b 1.10 ± 0.16
O1 1.06 ± 0.21 0.75 ± 0.12 a 1.04 ± 0.16
O2 0.94 ± 0.12 0.93 ± 0.04 b 0.99 ± 0.16
O3 1.11 ± 0.19 0.91 ± 0.09 b 1.04 ± 0.20
a,b Different superscripts in the same column mean significant difference at p < 0.05 level. O1: 106 µg OTA/kg feed,
O2: 654 µg OTA/kg feed, O3: 1126 µg OTA/kg feed.
4. Discussion
The present in vivo sub-chronic experiment demonstrated that OTA exposition significantly
increased free radical formation in the liver and kidney. OTA distributed into different tissues more or
less equally after oral intake [39], therefore its effects were possibly the same at the same time in both
tissues. Oxidative stress is proposed as the effect of OTA toxicity both in the liver [40] and kidney [41],
and the oxidative reactions activate lipid peroxidation [42]. These findings were partly supported by
the results of the present study because the initial phase of lipid peroxidation, amount of CD and CT,
did not increase. However, it reached the termination phase, as proven by the higher MDA content,
possibly due to the long-term period of exposure. The changes were more marked in the liver than
in the kidney, but in both tissues only the highest OTA dose (1126 µg/kg feed) revealed significant
changes. These results suggested that the cellular defence mechanism was unable to inhibit the lipid
peroxidation processes at that dose.
These results can be explained with the changes of the glutathione redox parameters,
because neither GSH content nor GPx activity increased systematically during the period of OTA
exposure. This meant that the amount or activity of the glutathione redox system was not adequate for
the elimination of oxygen free radicals, in particular at high OTA exposure.
On the other hand, the expression of the redox sensitive gene, KEAP1, was overexpressed in the
liver and downregulated in the kidney. This meant that release of Nrf2, as a transcription activator of
the Antioxidant Response Element (ARE) gene cluster [43], might have been released from the binding
with Keap1 in the kidney, but much less efficiently in the liver. However, at the same time the relative
expression of the NRF2 gene increased in both the liver and kidney, as a response to oxidative stress,
but hypothetically Nrf2 remains bounded to Keap1 in the liver, if the same changes occurred also at
the protein expression level, however, it was not determined in this study.
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A higher level of unbound Nrf2 activates the ARE containing genes encoding glutathione
metabolism enzymes, such as GSS, GSR and glutathione peroxidases (in this study GPX3 and GPX4).
Non-significant changes in GSH concentration together with downregulation of the gene expression
of GSS suggests that the cellular concentration of GSH did not change, because GSS protein is
required for the synthesis of GSH. This result was supported by previous studies where OTA exposure
down-regulated the genes involved in GSH metabolism [9,21], but contradictory with another in
rats [44], where a significant decrease of GSH concentration was found in the kidney. The possible cause
of this contradiction would be the higher OTA exposure applied in the previous study, and probably
another mechanism, for instance, the conjugation of OTA with GSH [45] which may also result in
a lower concentration. GSR expression also did not increase as an effect of OTA exposure, which meant
that the reduction of glutathione-disulphide (GSSG) to GSH was also not effective, which also supported
the insufficient antioxidant response in the liver and kidney, therefore induction of oxidative stress
and consequently lipid peroxidation. However, it should be noted that GSH homeostasis in the
cell is regulated by its synthesis and/or recycling, and also by the rate of utilization and eﬄux [46].
GPX3 encodes the extracellular glutathione peroxidase (GPx3), which mainly originates from kidney
tubular cells [47]. The overexpression in the kidney proves the importance of the kidney as a source of
GPx3, but an opposite tendency, downregulation, occurred in the liver, which has less importance in the
synthesis of this GPx isoenzyme. This difference in the gene expression also suggests that regulation of
glutathione peroxidase genes, in particular GPX3, in the kidney is more sensitive to oxidative stress
caused by OTA exposure than in the liver. However, higher relative gene expression did not manifest
at the protein level because there were no significant changes in GPx activity in the blood, even at
overexpression of kidney-origin GPX3, which meant that such an increase did not cause a significantly
higher amount of enzymatically active proteins. The other glutathione peroxidase enzyme, GPX4,
expression at both gene and protein levels occurred in most of the cell types, due to its effect on the
inhibition of membrane phospholipid oxidation [48]. However, its gene expression did not change in
the liver, and was downregulated in the kidney. At the protein level, the activity of GPx did not change
as an effect of OTA, which suggested that even in the case of downregulation of gene expression the
enzyme activity remains stable, possibly due to the post-translation modification of the preformed
enzyme proteins [49].
In conclusion, the results of the present study have revealed that OTA initiates free radical
formation both in the liver and kidney, but not in blood. The results showed that lipid peroxidation
depended on the length of exposure and the dose applied. Lack of ARE activation, which was suggested
by the low mRNA level of most of the Nrf2 dependent genes, resulted in improper antioxidant defence,
thus mild oxidative stress, even at the regulatory dose proposed by the European Commission for
poultry diets. Based on the results, defining lower values for poultry diets can be proposed and
attention should be placed on the use of feed additives, such as phytobiotics, which are useful for
activation of the antioxidant gene cluster [50], possibly even in the case of OTA exposure.
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